High-dose vitamin D3 during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial

被引:450
|
作者
Martineau, Adrian R. [1 ,4 ]
Timms, Peter M. [5 ]
Bothamley, Graham H. [5 ]
Hanifa, Yasmeen [1 ]
Islam, Kamrul [1 ]
Claxton, Alleyna P. [5 ]
Packe, Geoffrey E. [6 ]
Moore-Gillon, John C. [7 ,8 ]
Darmalingam, Mathina [9 ]
Davidson, Robert N. [10 ]
Milburn, Heather J. [11 ]
Baker, Lucy V. [12 ]
Barker, Richard D. [13 ]
Woodward, Nicholas J. [14 ]
Venton, Timothy R. [5 ]
Barnes, Korina E. [5 ]
Mullett, Christopher J. [5 ]
Coussens, Anna K. [4 ]
Rutterford, Clare M. [1 ]
Mein, Charles A. [3 ]
Davies, Geraint R. [15 ]
Wilkinson, Robert J. [4 ]
Nikolayevskyy, Vladyslav [2 ]
Drobniewski, Francis A. [2 ]
Eldridge, Sandra M. [1 ]
Griffiths, Christopher J. [1 ]
机构
[1] Queen Mary Univ London, Barts & London Sch Med & Dent, London E1 2AT, England
[2] Barts & London Queen Marys Sch Med & Dent, HPA Natl Mycobacterium Reference Lab, London, England
[3] Barts & London Queen Marys Sch Med & Dent, Genome Ctr, London, England
[4] Natl Inst Med Res, Div Mycobacterial Res, London NW7 1AA, England
[5] Homerton Univ NHS Fdn Trust, London, England
[6] Newham Chest Clin, London, England
[7] St Bartholomews Hosp, Dept Resp Med, London, England
[8] Royal London Hosp, Dept Resp Med, London E1 1BB, England
[9] Whipps Cross Univ Hosp, Dept Resp Med, London, England
[10] Northwick Pk Hosp & Clin Res Ctr, TB Clin, Harrow HA1 3UJ, Middx, England
[11] Guys & St Thomas NHS Fdn Trust, Dept Resp Med, London, England
[12] Lewisham Hosp, Dept Resp Med, London, England
[13] Kings Coll London, Dept Resp Med, London WC2R 2LS, England
[14] Royal Free Hosp, Dept Radiol, London NW3 2QG, England
[15] Univ Liverpool, Sch Clin Sci, Liverpool L69 3BX, Merseyside, England
来源
LANCET | 2011年 / 377卷 / 9761期
关键词
MESSENGER-RNA STABILITY; MYCOBACTERIUM-TUBERCULOSIS; CLINICAL-TRIAL; POLYMORPHISMS; CATHELICIDIN; RIFAMPICIN; SURVIVAL; OUTCOMES; DENSITY;
D O I
10.1016/S0140-6736(10)61889-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Vitamin D was used to treat tuberculosis in the pre-antibiotic era, and its metabolites induce antimycobacterial immunity in vitro. Clinical trials investigating the effect of adjunctive vitamin D on sputum culture conversion are absent. Methods We undertook a multicentre randomised controlled trial of adjunctive vitamin D in adults with sputum smear-positive pulmonary tuberculosis in London, UK. 146 patients were allocated to receive 2.5 mg vitamin D-3 or placebo at baseline and 14, 28, and 42 days after starting standard tuberculosis treatment. The primary endpoint was time from initiation of antimicrobial treatment to sputum culture conversion. Patients were genotyped for TaqI and FokI polymorphisms of the vitamin D receptor, and interaction analyses were done to assess the influence of the vitamin D receptor genotype on response to vitamin D3. This trial is registered with ClinicalTrials.gov number NCT00419068. Findings 126 patients were included in the primary efficacy analysis (62 assigned to intervention, 64 assigned to placebo). Median time to sputum culture conversion was 36.0 days in the intervention group and 43.5 days in the placebo group (adjusted hazard ratio 1.39, 95% CI 0.90-2.16; p=0.14). TaqI genotype modified the effect of vitamin D supplementation on time to sputum culture conversion (p(interaction)=0.03), with enhanced response seen only in patients with the tt genotype (8.09, 95% CI 1.36-48.01; p=0.02). FokI genotype did not modify the effect of vitamin D supplementation (p(interaction)=0.85). Mean serum 25-hydroxyvitamin D concentration at 56 days was 101.4 nmol/L in the intervention group and 22.8 nmol/L in the placebo group (95% CI for difference 68.6-88.2; p<0.0001). Interpretation Administration of four doses of 2.5 mg vitamin D3 increased serum 25-hydroxyvitamin D concentrations in patients receiving intensive-phase treatment for pulmonary tuberculosis. Vitamin D did not significantly affect time to sputum culture conversion in the whole study population, but it did significantly hasten sputum culture conversion in participants with the tt genotype of the TaqI vitamin D receptor polymorphism.
引用
收藏
页码:242 / 250
页数:9
相关论文
共 50 条
  • [31] HIGH-DOSE INTRAVENOUS ACYCLOVIR IN THE TREATMENT OF ZOSTER - A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    JUELJENSEN, BE
    KHAN, JA
    PASVOL, G
    JOURNAL OF INFECTION, 1983, 6 : 31 - 36
  • [32] A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF HIGH-DOSE PREDNISONE FOR THE TREATMENT OF POSTPOLIOMYELITIS SYNDROME
    DINSMORE, S
    DAMBROSIA, J
    DALAKAS, MC
    POST-POLIO SYNDROME: ADVANCES IN THE PATHOGENESIS AND TREATMENT, 1995, 753 : 303 - 313
  • [33] Effect of high-dose cholecalciferol (vitamin D3) on bone and body composition in children and young adults with HIV infection: a randomized, double-blind, placebo-controlled trial
    A. J. Rovner
    V. A. Stallings
    R. Rutstein
    J. I. Schall
    M. B. Leonard
    B. S. Zemel
    Osteoporosis International, 2017, 28 : 201 - 209
  • [34] Effect of high-dose cholecalciferol (vitamin D3) on bone and body composition in children and young adults with HIV infection: a randomized, double-blind, placebo-controlled trial
    Rovner, A. J.
    Stallings, V. A.
    Rutstein, R.
    Schall, J. I.
    Leonard, M. B.
    Zemel, B. S.
    OSTEOPOROSIS INTERNATIONAL, 2017, 28 (01) : 201 - 209
  • [35] High-dose ursodeoxycholic acid in primary sclerosing cholangitis a randomised double-blind placebo-controlled trial
    Bansi, D
    Christie, J
    Fleming, K
    Chapman, R
    GASTROENTEROLOGY, 1996, 110 (04) : A1146 - A1146
  • [36] Double-blind randomised controlled trial of vitamin D3 supplementation for the prevention of acute respiratory infection in older adults and their carers (ViDiFlu)
    Martineau, Adrian R.
    Hanifa, Yasmeen
    Witt, Karolina D.
    Barnes, Neil C.
    Hooper, Richard L.
    Patel, Mital
    Stevens, Natasha
    Enayat, Zinat
    Balayah, Zuhur
    Syed, Asmat
    Knight, Aishah
    Jolliffe, David A.
    Greiller, Claire L.
    McLaughlin, David
    Venton, Timothy R.
    Rowe, Marion
    Timms, Peter M.
    Clark, Duncan
    Sadique, Zia
    Eldridge, Sandra M.
    Griffiths, Christopher J.
    THORAX, 2015, 70 (10) : 953 - 960
  • [37] Effect of Vitamin D3 Supplementation on Acute Fracture Healing: A Phase II Screening Randomized Double-Blind Controlled Trial
    Slobogean, Gerard P.
    Bzovsky, Sofia
    O'Hara, Nathan N.
    Marchand, Lucas S.
    Hannan, Zachary D.
    Demyanovich, Haley K.
    Connelly, Daniel W.
    Adachi, Jonathan D.
    Thabane, Lehana
    Sprague, Sheila
    Vita-Shock Investigators
    JBMR PLUS, 2023, 7 (01)
  • [38] A Randomised, Double-Blind, Placebo-Controlled Trial with Vitamin D3 in MS: Subgroup Analysis of Patients with Baseline Disease Activity Despite Interferon Treatment
    Aivo, J.
    Lindsrom, B. -M.
    Soilu-Hanninen, Andm.
    MULTIPLE SCLEROSIS INTERNATIONAL, 2012, 2012
  • [39] A DOUBLE-BLIND CONTROLLED TRIAL OF HIGH-DOSE INTRAVENOUS METHYL PREDNISOLONE IN THE TREATMENT OF MULTIPLE-SCLEROSIS
    MILLIGAN, NM
    HUGHES, PJ
    COMPSTON, DAS
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1986, 49 (04): : 478 - 478
  • [40] Effect of Single High-Dose Vitamin D3 Supplementation on Post-Ultra Mountain Running Heart Damage and Iron Metabolism Changes: A Double-Blind Randomized Controlled Trial
    Stankiewicz, Blazej
    Mieszkowski, Jan
    Kochanowicz, Andrzej
    Brzezinska, Paulina
    Niespodzinski, Bartlomiej
    Kowalik, Tomasz
    Waldzinski, Tomasz
    Kowalski, Konrad
    Borkowska, Andzelika
    Reczkowicz, Joanna
    Danilowicz-Szymanowicz, Ludmila
    Antosiewicz, Jedrzej
    NUTRIENTS, 2024, 16 (15)